STOCK TITAN

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
management
Rhea-AI Summary

I-Mab (NASDAQ: IMAB) has announced the appointment of Dr. Phillip Dennis as Chief Medical Officer, effective June 17, 2024. Dr. Dennis will lead I-Mab's global clinical development and join the Executive Leadership Team. With two decades of oncology drug development experience, including key roles at Sanofi and AstraZeneca, Dr. Dennis brings significant expertise. His appointment aims to advance I-Mab's clinical pipeline, particularly for treatments like uliledlimab, givastomig, and ragistomig. Before his industry roles, Dr. Dennis was a professor at Johns Hopkins University and a senior investigator at the US National Cancer Institute.

Positive
  • Appointment of Dr. Phillip Dennis as CMO, bringing over two decades of experience in oncology drug development.
  • Dr. Dennis's previous experience includes leadership roles at Sanofi and AstraZeneca, contributing to the development of key cancer treatments.
  • Dr. Dennis to lead global clinical development efforts, potentially accelerating I-Mab's clinical pipeline progress.
  • Focus on key therapies like uliledlimab, givastomig, and ragistomig, which have shown promising data in advanced solid tumors.
Negative
  • Potential risks associated with a new CMO adjusting to the company's strategic vision and operational dynamics.
  • No immediate financial benefits or clinical trial results were reported in the PR, which may not positively impact stock prices in the short term.

ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.

"I am pleased to welcome Dr. Phillip Dennis as our Chief Medical Officer. Dr. Dennis brings over two decades of experience in oncology drug development, including his role as a cross-functional leader of the international team that developed a novel PD-L1 inhibitor and his contributions to the development of other assets for lung and other cancers." said Raj Kannan, CEO of I-Mab. "I look forward to partnering with Phillip in further advancing our clinical development pipeline and unlocking the potential of I-Mab for patients and shareholders."

"I am pleased to join I-Mab at this critical juncture in the Company's growth," said Dr. Dennis. " I am excited about the opportunity for uliledlimab, givastomig, and ragistomig, based on data from monotherapy and combination therapy in advanced solid tumors, including lung and gastric cancers, presented at major medical meetings to date. I look forward to working with my accomplished colleagues to support the accelerated development of I-Mab's clinical pipeline."  

Before joining I-Mab, Dr. Dennis was Vice President of Lung Cancer Strategy and the Global Project Head for a novel, first-in-class ADC at Sanofi (NASDAQ: SNY). Prior to Sanofi, Dr. Dennis was Vice President of Lung Cancer Strategy and Global Clinical Lead at AstraZeneca (NASDAQ: AZN). In these roles, Dr. Dennis served as the disease strategy head for lung cancer and led the cross-functional development of key assets, including IMFINZI®. Prior to his pharmaceutical career, Dr. Dennis was a widely published professor of Oncology, Medicine, and Pharmacology at Johns Hopkins University. Dr. Dennis received his MS, MD, and PhD degrees from the New York University School of Medicine as part of the Medical Scientist Training Program. Dr. Dennis completed his residency in Internal Medicine and fellowship in Medical Oncology at Johns Hopkins. Dr. Dennis also spent 14 years as a translational researcher at the US National Cancer Institute, achieving tenure as a Senior Investigator. He is an elected member of the American Society for Clinical Investigation and has won several awards, including an NIH Merit Award.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer.

I-Mab has established operations in the U.S. in Rockville, Maryland, and in San Diego, California. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

IMFINZI® is a registered trademark of AstraZeneca.

I-Mab Forward Looking Statements

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "believes", "designed to", "anticipates", "future", "intends", "plan", "promise", "potential", "estimate", "confident", "explore", "optimistic about", "look forward to", and similar terms or the negative thereof. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. The forward-looking statements in this press release include, without limitation, statements regarding: the anticipated terms, objectives, and potential for its clinical pipeline, including uliledlimab, givastomig, and ragistomig. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or New Drug Application/Biologics License Application approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and discussions of potential risks, uncertainties, and other important factors in I-Mab's most recent annual report on Form 20-F and I-Mab's subsequent filings with the U.S. Securities and Exchange Commission (the "SEC"). I-Mab may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

I-Mab Contacts

Investors & Media

Tyler Ehler

Senior Director, Investor Relations

IR@imabbio.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-appoints-phillip-dennis-md-phd-as-chief-medical-officer-302165433.html

SOURCE I-Mab Biopharma

FAQ

When will Dr. Phillip Dennis join I-Mab as Chief Medical Officer?

Dr. Phillip Dennis will join I-Mab as Chief Medical Officer on June 17, 2024.

What experience does Dr. Phillip Dennis bring to I-Mab?

Dr. Phillip Dennis has over two decades of experience in oncology drug development, including leadership roles at Sanofi and AstraZeneca.

What are the key therapies Dr. Dennis will focus on at I-Mab?

Dr. Dennis will focus on uliledlimab, givastomig, and ragistomig, which have shown promising data in advanced solid tumors.

What is the significance of Dr. Dennis's appointment for I-Mab?

Dr. Dennis's appointment is expected to accelerate I-Mab's global clinical development efforts and advance its clinical pipeline.

What was Dr. Dennis's previous role before joining I-Mab?

Before joining I-Mab, Dr. Dennis was the Vice President of Lung Cancer Strategy and Global Project Head at Sanofi.

AstraZeneca PLC

NASDAQ:AZN

AZN Rankings

AZN Latest News

AZN Stock Data

245.69B
1.55B
0.01%
16.87%
0.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Cambridge